Therapeutic value of endoscopic retrograde cholangiopancreatography for liver cirrhosis combined with biliopancreatic diseases

中华消化内镜杂志 Pub Date : 2020-02-20 DOI:10.3760/CMA.J.ISSN.1007-5232.2020.02.009

Wen-bin Ran, Jielin Li, J. Gan, Yanglin Pan, Xuegang Guo

{"title":"Therapeutic value of endoscopic retrograde cholangiopancreatography for liver cirrhosis combined with biliopancreatic diseases","authors":"Wen-bin Ran, Jielin Li, J. Gan, Yanglin Pan, Xuegang Guo","doi":"10.3760/CMA.J.ISSN.1007-5232.2020.02.009","DOIUrl":null,"url":null,"abstract":"Objective \nTo evaluate the efficacy and safety of endoscopic retrograde cholangiopancreatography (ERCP) for patients with liver cirrhosis combined with biliopancreatic diseases. \n \n \nMethods \nData of 99 patients with liver cirrhosis combined with biliopancreatic diseases who received ERCP at Xijing Digestive Hospital from November 2008 to December 2017 for the first time were retrospectively studied. Success rate of ERCP and incidence of complications were analyzed. \n \n \nResults \nThe 99 cases of liver cirrhosis were mainly caused by hepatitis B virus infection (40.4%, 40/99) and unknown reasons (30.3%, 30/99), and the mean model for end-stage liver disease score was 15.4±5.3. The common bile duct stones and bile duct stricture were the most common biliopancreatic diseases, accounting for 49.5% (49/99) and 33.3% (33/99), respectively. The success rate of ERCP was 100.0%(99/99). The total postoperative complication incidence was 14.1% (14/99), among which liver cirrhosis-related complications was 3.0% (3/99); ERCP-related complications was 11.1% (11/99), including 9.1% (9/99) biliary tract infection, and 2.0% (2/99) delayed bleeding. No post-ERCP pancreatitis, perforation or death occurred. \n \n \nConclusion \nERCP is safe and effective for liver cirrhosis combined with biliopancreatic diseases. \n \n \nKey words: \nLiver cirrhosis; Choledocholithiasis; Cholangiopancreatography, endoscopic retrograde; Postoperative complications; Biliary stricture","PeriodicalId":10072,"journal":{"name":"中华消化内镜杂志","volume":"37 1","pages":"121-124"},"PeriodicalIF":0.0000,"publicationDate":"2020-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华消化内镜杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1007-5232.2020.02.009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To evaluate the efficacy and safety of endoscopic retrograde cholangiopancreatography (ERCP) for patients with liver cirrhosis combined with biliopancreatic diseases. Methods Data of 99 patients with liver cirrhosis combined with biliopancreatic diseases who received ERCP at Xijing Digestive Hospital from November 2008 to December 2017 for the first time were retrospectively studied. Success rate of ERCP and incidence of complications were analyzed. Results The 99 cases of liver cirrhosis were mainly caused by hepatitis B virus infection (40.4%, 40/99) and unknown reasons (30.3%, 30/99), and the mean model for end-stage liver disease score was 15.4±5.3. The common bile duct stones and bile duct stricture were the most common biliopancreatic diseases, accounting for 49.5% (49/99) and 33.3% (33/99), respectively. The success rate of ERCP was 100.0%(99/99). The total postoperative complication incidence was 14.1% (14/99), among which liver cirrhosis-related complications was 3.0% (3/99); ERCP-related complications was 11.1% (11/99), including 9.1% (9/99) biliary tract infection, and 2.0% (2/99) delayed bleeding. No post-ERCP pancreatitis, perforation or death occurred. Conclusion ERCP is safe and effective for liver cirrhosis combined with biliopancreatic diseases. Key words: Liver cirrhosis; Choledocholithiasis; Cholangiopancreatography, endoscopic retrograde; Postoperative complications; Biliary stricture

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

内窥镜逆行胰胆管造影对肝硬化合并胆胰疾病的治疗价值

目的评价内窥镜逆行胰胆管造影(ERCP)治疗肝硬化合并胆胰疾病的疗效和安全性。方法回顾性分析西京消化医院2008年11月至2017年12月首次行ERCP治疗的99例肝硬化合并胆胰疾病患者的资料。分析ERCP的成功率及并发症的发生率。结果99例肝硬化以乙型肝炎病毒感染(40.4%，40/99)和未知原因(30.3%，30/99)为主，终末期肝病模型平均评分为15.4±5.3。胆胰疾病以胆总管结石和胆管狭窄最为常见，分别占49.5%(49/99)和33.3%(33/99)。ERCP成功率为100.0%(99/99)。术后并发症总发生率14.1%(14/99)，其中肝硬化相关并发症3.0% (3/99);ercp相关并发症为11.1%(11/99)，其中胆道感染9.1%(9/99)，迟发性出血2.0%(2/99)。无ercp术后胰腺炎、穿孔或死亡发生。结论ERCP治疗肝硬化合并胆胰疾病安全有效。关键词:肝硬化;黄疸;胆管造影，内镜逆行;术后并发症;胆道狭窄

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

中华消化内镜杂志

CiteScore

0.10

自引率

0.00%

发文量

7555

期刊介绍： Chinese Journal of Digestive Endoscopy is a high-level medical academic journal specializing in digestive endoscopy, which was renamed Chinese Journal of Digestive Endoscopy in August 1996 from Endoscopy. Chinese Journal of Digestive Endoscopy mainly reports the leading scientific research results of esophagoscopy, gastroscopy, duodenoscopy, choledochoscopy, laparoscopy, colorectoscopy, small enteroscopy, sigmoidoscopy, etc. and the progress of their equipments and technologies at home and abroad, as well as the clinical diagnosis and treatment experience. The main columns are: treatises, abstracts of treatises, clinical reports, technical exchanges, special case reports and endoscopic complications. The target readers are digestive system diseases and digestive endoscopy workers who are engaged in medical treatment, teaching and scientific research. Chinese Journal of Digestive Endoscopy has been indexed by ISTIC, PKU, CSAD, WPRIM.